Research ArticleClinical Investigation
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
Journal of Nuclear Medicine October 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727
Claudia Ortega
1Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada;
Rebecca K.S. Wong
2Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada;
Josh Schaefferkoetter
3Siemens Medical Solutions USA, Inc., Knoxville, Tennessee;
Patrick Veit-Haibach
1Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada;
Sten Myrehaug
4Division of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada;
Rosalyn Juergens
5Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada;
David Laidley
6Division of Nuclear Medicine, St. Joseph’s Health Care London, University of Western Ontario, London, Ontario, Canada; and
Reut Anconina
1Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada;
Amy Liu
7Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Ur Metser
1Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue 10
October 1, 2021
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu, Ur Metser
Journal of Nuclear Medicine Oct 2021, 62 (10) 1406-1414; DOI: 10.2967/jnumed.120.256727
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu, Ur Metser
Journal of Nuclear Medicine Oct 2021, 62 (10) 1406-1414; DOI: 10.2967/jnumed.120.256727